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Oncolytic viral therapies have recently found their way into clinical application for hepa-
tocellular carcinoma (HCC), a disease with limited treatment options and poor prognosis.
Adding to the many intrinsic challenges of in vivo oncolytic viral therapy, is the complex
microenvironment of the liver, which imposes unique limitations to the successful deliv-
ery and propagation of the virus. The normal liver milieu is characterized by an intricate
network of hepatocytes and non-parenchymal cells including Kupffer cells, stellate cells,
and sinusoidal endothelial cells, which can secrete anti-viral cytokines, provide a platform
for non-specific uptake, and form a barrier to efficient viral spread. In addition, natural killer
cells are greatly enriched in the liver, contributing to the innate defense against viruses.The
situation is further complicated when HCC arises in the setting of underlying hepatitis virus
infection and/or hepatic cirrhosis, which occurs in more than 90% of clinical cases. These
conditions pose further inhibitory effects on oncolytic virus (OV) therapy due to the pres-
ence of chronic inflammation, constitutive cytokine expression, altered hepatic blood flow,
and extracellular matrix deposition. In addition, OVs can modulate the hepatic microenvi-
ronment, resulting in a complex interplay between virus and host. The immune system
undoubtedly plays a substantial role in the outcome of OV therapy, both as an inhibitor of
viral replication, and as a potent mechanism of virus-mediated tumor cell killing.This review
will discuss the particular challenges of oncolytic viral therapy for HCC, as well as some
potential strategies for modulating the immune system and synergizing with the hepatic
microenvironment to improve therapeutic outcome.
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INTRODUCTION
Hepatocellular carcinoma (HCC), representing over 90% of all
cases of primary liver cancer, is the sixth most common form
of cancer and the third leading cause of cancer-related mortal-
ity worldwide (1, 2). Due to the advanced stage at which most
patients are diagnosed, only a small percentage are eligible for
potentially curative resection, local ablation, or liver transplan-
tation (3). HCC is highly refractory to chemotherapy and other
systemic treatments, and local regional therapies such as transar-
terial chemoembolization (TACE) or selective internal radiation
therapy (SIRT) are largely palliative. Recently, the multi-kinase
inhibitor, sorafenib, was found to be effective in patients with
advanced HCC and is currently the standard of care in these
patients; however the prolongation of survival associated with
sorafenib therapy is under 3 months (4), and the median sur-
vival for patients with advanced stage, unresectable HCC is less
than 1 year (3). The lack of effective treatment options for HCC
underlines the need for novel alternative therapies such as those
employing oncolytic viruses (OVs).
We have previously demonstrated in a preclinical rat model
that oncolytic vesicular stomatitis virus (VSV) and Newcastle
disease virus (NDV) both replicate well and cause significant
tumor-specific cell lysis in orthotopic HCC, leading to substan-
tial survival prolongation (5–7). Based on preclinical data such as
these, OVs have been applied in various clinical trials in cancer
patients. However, as more and more data are accumulated from
clinical trials, it is becoming evident that the significant efficacy
reported for OVs in preclinical animal models is not readily trans-
latable to the clinic, due to the vast complexities of spontaneous
malignant transformation in the immune-competent setting in
patients.
Although these challenges are universal to OVs regardless of the
tumor target, the dynamic setting of the liver presents a unique set
of hurdles, which viruses must surpass in order to exert their ther-
apeutic effects against HCC. The liver microenvironment consists
of a complex network of hepatocytes, stromal cells, inflammatory
cells, and extracellular matrix (ECM). HCC is an inflammation-
driven cancer (8), and the chronic inflammatory state, character-
ized by the recruitment of inflammatory cells and high levels of
cytokine expression, not only promotes tumorigenesis (9), but it
also serves to provide a basis for innate immunity against OVs.
Although it may seem contradictory that hepatotropic viruses
manage to escape immune surveillance and establish chronic
infections in the liver, this paradox can be attributed to intrinsic
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differences among viruses,whereby the hepatitis viruses are known
to possess various mechanisms for evading or interfering with the
immune system (10, 11). Whether or not the well-characterized
feature of immune tolerance in the liver actually plays a role in pro-
moting OV replication in liver tumors is not known; however, OVs
are extremely sensitive to the anti-viral actions of type I interferon
(IFN), and this is most likely the primary mechanism by which the
replication of OVs is limited in vivo.
When HCC arises as a consequence of chronic hepatitis virus
infection and in the setting of hepatic fibrosis, the liver milieu
is distorted and provides a platform for dynamic interactions
between OVs and the liver microenvironment. In Greek mythol-
ogy, Pandora’s box was actually a large and beautiful jar, which
contained all the evils of the world. At first glance, the diseased
liver can resemble a Pandora’s box of sorts, filled with a variety of
“evils” that present unique challenges to conventional therapies.
As we learn more about the pathogenesis of liver disease, we can
actually exploit the unique features of the local microenvironment
to synergize with OV therapy and thereby transform Pandora’s box
from a vessel of evil into a platform of hope for new therapeutic
targets. In this review, we will discuss the complex interactions
between OVs and the liver milieu and present novel strategies for
improving the therapeutic outcome.
THE COMPLEX LIVER MILIEU AND ITS IMPACT ON OV
THERAPY OF HCC
The liver is arguably one of the most vital organs of the body, due
to its diverse roles in metabolism, nutrient uptake, detoxification,
and immune modulation. Because of the complexity of functions,
the liver architecture is composed of an intricate network of cells
and ECM to ensure that each task can be performed efficiently.
Although this system is crucial for the proper functioning of the
liver, it poses various barriers to the ability of OVs to infect and
replicate well in hepatic tumors. In this section, the various aspects
of the liver microenvironment, which challenge the fate of OVs in
HCC therapy (summarized in Figure 1), as well as the unique
interactions between OVs and the liver milieu, will be discussed.
THE HEALTHY LIVER SETTING
Although the majority of HCCs arise in the context of underly-
ing chronic liver disease, a small percentage can develop in the
absence of advanced hepatic fibrosis, or even in a healthy liver
setting (12). Hepatocytes constitute the majority of the liver vol-
ume (approximately 80%), and they are protected from invading
organisms in the bloodstream by non-parenchymal cells lining the
liver sinusoids. The major sinusoidal components are Kupffer cells
(KCs), liver sinusoidal endothelial cells (LSECs), hepatic stellate
cells (HSCs), and natural killer (NK) cells. A unique microvascu-
lature, including the fenestration of sinusoidal endothelial cells,
acts as a filtration system to trap pathogens, waste products, and
circulating tumor cells, making the liver a common site for tumor
metastases. KCs are resident macrophages of the liver and are con-
sidered to be scavenger cells, playing a major role in removing
foreign material from portal circulation (13). Together with NK
cells and dendritic cells (DCs), KCs are important components of
the innate immune system, providing a rapid first line of defense
against invading pathogens and protecting the liver from bacterial
and viral infections (14). Despite the crucial protective function of
KCs in the liver, hepatic sequestration and destruction of viruses
is a universal limitation to all systemically applied OVs, and they
can pose a particular challenge to viral therapies targeting HCC
cells, due to their close proximity. Following uptake, the KC, as
well as engulfed viruses, are rapidly degraded, greatly reducing
the bioavailability of the virus (15, 16). It is well established that
therapeutic doses of adenovirus must first saturate the KC pop-
ulation before their effects can be seen in target cells (17, 18).
To illustrate this point, it was demonstrated for adenovirus type
5 that up to 90% of injected viral particles are sequestered from
the blood by KCs (19), and depletion of KCs via predosing with
adenovirus or pretreatment with clodronate results in improved
bioavailability and anti-tumor efficacy of adenovirus therapy (20,
21). In addition, activated KCs are potent producers of nitric oxide
and cytokines such as IFN, TNF-α, IL-6, and IL-10 (13, 22, 23),
all of which have potent anti-viral functions (24, 25) and likely
contribute to the local control of OV replication in HCCs.
In addition to KCs, the LSECs, which are specialized endothe-
lial cells lining the liver sinusoid, belong to the reticuloendothelial
system and play a role in clearing materials from the bloodstream.
They have been shown to be important in eliminating circulating
adenovirus particles (15, 26) via scavenger receptors expressed on
the cell surface (18). Although less information is available regard-
ing the role of KCs and LSECs in the depletion of other OVs from
the blood, it is speculated that the same mechanism identified for
adenovirus applies to these viruses as well (27–29).
Natural killer or “pit cells,” and NKT cells are enriched and
constitutively activated in the sinusoid of normal, healthy liv-
ers, and are key players in innate immune surveillance (30, 31).
These cells represent a distinct subset of the cytotoxic lymphocyte
population and are crucial in the early defense against invading
viruses (32), prior to the launch of adaptive immune responses
(33–35). It is speculated that bone marrow-derived peripheral
NK cells migrate to the liver (36), where they are stimulated by
hepatic cells, such as KCs (37), causing them to differentiate and
become activated and express DC markers (38). Liver-specific NK
cells are immunologically, morphologically, and functionally dif-
ferent from peripheral NK cells, expressing higher levels of TRAIL,
performin, and granzyme B, and having a higher percentage of
activated populations, presumably contributing to the increased
cytotoxicity of liver NK cells (30, 39). Upon activation, NK cells
mediate the direct lysis of target cells by releasing copious amounts
of cytokines and cytotoxic granules, or by induction of apoptosis
(40, 41). As crucial components of the cellular response to viral
infections, it is not surprising that NK cells also have an inhibitory
effect on OVs. To illustrate this point, it was demonstrated in vitro
that NK cells rapidly and specifically lyse tumor cells at an early
stage of infection with herpes simplex type 1 or vaccinia virus and
prevent viral propagation and spread to neighboring cells (35). We
have observed a significant intratumoral accumulation of NK and
NKT cells in orthotopic, syngeneic HCC in immune-competent
rats within 24 h of treatment with oncolytic VSV and have demon-
strated that these cells play a major role in the rapid clearance of the
virus (42). We believe that this rapid innate response is at least par-
tially mediated by the large number of resident NK and NKT cells
which are present in the liver and can immediately infiltrate areas
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FIGURE 1 | Features of the hepatic microenvironment which challenge
the fate of OVs. The innate immune response in the liver consists of
scavenger Kupffer cells (KCs) and liver sinusoidal endothelial cells (LSECs)
and resident NK and NKT cells, which are efficient at clearing invading
oncolytic viruses from the liver. KCs and NK/NKT cells secrete a variety of
antiviral cytokines in response to infection, which substantially limit the
replication of OVs in hepatocellular carcinoma (HCC). Material from dying
virus-infected cells mediates cross-priming of T-cell responses by dendritic
cells (DCs) and thereby induces an adaptive immune response against the
virus. Hepatic stellate cells, which reside in the space of Disse, become
activated during tumorigenesis causing them to migrate and secrete
copious amounts of extracellular matrix (ECM) components, which hinder
intratumoral cell-to-cell spread of OVs. Infected hepatocytes enter an
anti-viral state and secrete type I interferons (IFNs), which protect the
neighboring liver cells from infection and could also infer protection to HCC
cells that are partially sensitive to IFN.
of VSV infection to prevent productive replication and spread of
the virus and thereby inhibit the therapeutic effect.
THE DISEASED LIVER
In nearly 90% of HCC patients, tumors arise as a consequence of
chronic liver injury, which provides an ideal setting for carcino-
genesis to occur (43, 44). Liver disease, caused by persistent viral,
toxic, autoimmune, metabolic, or cholestatic impairments, results
in a chronic inflammatory response marked by the secretion of a
cocktail of cytokines and chemokines by infiltrating immune cells
and the resident non-parenchymal cells. As a result, the hepatic
architecture becomes disrupted, as evidenced by hepatocyte pro-
liferation, the extensive deposition of ECM, nodule formation, and
the increased risk of HCC.
When HCC occurs in the midst of a chronically injured liver, the
already limited treatment options become even further restricted.
Although the application of OVs is an attractive alternative to the
palliative treatment options available to patients with advanced
liver disease, the fate of therapeutic viruses administered in this
complex setting is further challenged. Viral vectors targeting HCC
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in a diseased liver face many unfavorable conditions, including
accumulation of immune cells, constitutively activated cytokines,
dense ECM, and altered blood flow.
During the fibrogenic wound-healing process, HSCs differen-
tiate from the quiescent to the activated form with a myofibroblast
phenotype, which is marked by the loss of intracellular vitamin
A-rich fat droplets and expression of α-smooth muscle actin (α-
SMA). These transdifferentiated HSCs promote ECM remodeling
by deregulating the balance of matrix metalloproteinases (MMPs)
and tissue inhibitors of matrix metalloproteinases (TIMPs) and
resulting in the degradation of the normal basement membrane
and replacement with interstitial collagen (primarily type I and
III) and scar matrix. In addition, HSCs migrate and proliferate
in response to a variety of cytokines and growth factors elicited
during hepatic injury to further promote the progression of fibro-
sis, resulting in the distortion of the normal liver architecture and
leading to decompensated liver function.
The implication of the presence of hepatic fibrosis on the out-
come of OV therapy for HCC is complex, due to the multifaceted
nature of the interactions between OVs and the microenviron-
ment of the chronically injured liver. The presence of fibrotic tissue
throughout the liver likely provides a physical barrier to trap OVs
and prevent efficient delivery of viruses to tumor beds, and altered
patterns of blood flow limit the ability of systemically applied
viruses to reach their tumor targets. The aberrant microenviron-
ment within HCC, consisting of activated HSCs, inflammatory
cells, and extensive ECM deposition, not only further promotes
HCC growth, invasion, and metastasis, but also challenges viral
infection and spread among HCC cells. Although HCC is not
conventionally considered to be a fibrotic cancer, evidence has
shown a correlation between poor differentiation of HCC and
degree of ECM remodeling (45). Furthermore, the predominant
components of the ECM of HCC are the fibril-forming colla-
gens type I and III (46, 47), which are also dominant in hepatic
fibrosis tissue. Although we have not yet specifically investigated
this issue, it is likely that this intratumoral deposition of colla-
gen plays a role in containing viral spread and leading to the
well-defined foci of VSV replication that we observe in HCC
lesions (6).
The inflammatory milieu associated with chronic liver injury,
most often induced by hepatitis B or C virus infection, not only
contributes to the pathogenesis of fibrosis and HCC, but it also
threatens the ability of OVs to replicate and destroy tumor cells.
The acute response to liver injury involves the activation of resident
liver immune cells, followed by the recruitment of non-resident
immune cells to launch a potent cytokine response in the liver in
an attempt to lyse the infected or injured cells (48, 49). Hepati-
tis B virus (HBV) infection causes induction of NK cells and
cytotoxic T-cells (CD8+), which then secrete anti-viral cytokines,
such as IFN-γ and TNF-α (50, 51). Upon infection, the host rec-
ognizes the pathogen-associated molecular patterns (PAMPs) of
viral products via pathogen recognition receptor (PRR) proteins,
such as toll-like receptor 2 (TLR2). Activation of PRRs by HBV
leads to induction of transcription factors, such as NF-κB, and
the release of pro-inflammatory and anti-viral cytokines, such
as TNF-α, IL-6, and IL-10 (51, 52), all of which can inhibit OV
replication. Hepatitis C virus (HCV) infection causes an immune
response characterized by cytokines and non-specific lymphocyte
recruitment, which can also have inhibitory effects on OVs.
In addition to the potentially limited efficacy of oncolytic viral
therapy for HCC in the context of liver injury, there are valid
safety concerns associated with such a therapeutic approach. The
local cytokine induction following OV application in an already
inflamed liver could potentially cause a highly toxic “cytokine
storm” and hepatotoxicity, strongly contraindicating this strat-
egy. Furthermore, due to a lack of appropriate rodent models, the
interaction of an OV with an underlying hepatic viral infection
remains unclear. However, recent findings indicate that adminis-
tration of OVs could potentially provide a therapeutic benefit in
decreasing HBV load (53–55). In studies using inactivated Para-
poxvirus ovis (Orf virus), it was shown that viral therapy inhibited
human HBV and HCV, as well as herpes simplex virus infection,
without any signs of toxicity, in preclinical mouse models (53,
54). In these studies, it was demonstrated that inactivated Orf
virus-mediated induction of IFN-γ was a key mechanism in the
anti-viral activity, and the absence of hepatotoxicity was associated
with a down-regulation of antigen cross-presentation in LSECs. To
further illustrate this phenomenon, it was recently demonstrated
in a clinical trial in patients with HCC that, in addition to the anti-
tumoral and anti-vascular activities of oncolytic poxvirus JX-594,
virotherapy led to a suppression of underlying HBV replication
and caused a transient decrease in viral load (55).
Along similar lines, an exciting new body of research has
demonstrated antifibrotic effects mediated by OV therapy. It was
first reported in 2009 that NDV replicates selectively in activated
HSCs and causes reversal of hepatic fibrogenesis in mice (56).
Our own work similarly demonstrated the antifibrotic proper-
ties of oncolytic VSV, via replication and subsequent apoptosis of
activated HSCs, induction of NK cell infiltration, and gene modu-
lation in favor of fibrotic regression (57). Furthermore, in addition
to anti-viral activities, inactivated Orf virus has also been shown to
elicit antifibrotic effects in two preclinical models of liver fibrosis
(53, 58). These studies indicate that OV therapy in the context of
underlying hepatic injury is not only safe, but also could provide
additional therapeutic benefits to resolve liver disease.
Additionally, in light of these new findings, we may reevaluate
our classical view of tumor stroma as being a barrier to OV therapy.
Activated HSCs infiltrate the stroma of HCC and localize around
tumor sinusoids, capsules, and fibrous septa (59), and increasing
intratumoral density of activated HSCs is correlated with poor
prognosis (60). Data demonstrating the ability of OVs to replicate
specifically in activated HSCs imply that they may also replicate
within HCC-infiltrated HSCs.
STRATEGIES TO IMPROVE OV THERAPY FOR HCC
Although the potential of OV therapy for HCC has been demon-
strated, it is clear that novel strategies must be utilized in order
to enhance viral replication and/or virus-mediated anti-tumor
immune responses to improve therapeutic outcomes in the unique
and complex setting of the liver. A prominent theme in OV devel-
opment is the ongoing debate regarding the complex and contra-
dictory roles of the immune system, which can be considered both
inhibitory, in terms of the host’s anti-viral immune response, or
complementary, with respect to anti-tumoral immune responses
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Table 1 | Barriers to intrahepatic OV therapy and potential strategies
for overcoming them.
Barrier Strategy Reference
Non-specific uptake by
Kupffer cells
Predosing with OV (20)
Kupffer cell depletion (20, 21)
Viral shielding (64–67)
Innate anti-viral
response
Kupffer cell depletion (20, 21)
OV-mediated expression of
vCKBP
(42, 68, 69)
Poor viral replication
and/or spread
Combination therapies (62, 63, 70–72)
OV as immunotherapeutic (73–86)
Hepatic fibrosis Utilization of antifibrotic OVs (53, 56–58)
Underlying hepatic viral
infection
Utilization of anti-viral OVs (53–55)
which are crucial in clearing uninfected tumor cells and chal-
lenging tumor relapse. Although it remains to be seen whether
inhibition or augmentation of the immune response is the more
powerful therapeutic strategy, the ideal approach would undoubt-
edly involve selective inhibition of anti-viral immune components,
while simultaneously inducing a strong anti-tumoral immune
response. A comprehensive discussion of the competing roles
of the immune response in the efficacy of OV therapy, as well
as strategies to modulate the immune system to synergize with
OV therapy has been thoroughly reviewed elsewhere (61–63),
and therefore will not be recapitulated here. In this section, we
will review the general approaches for improving viral-mediated
oncolysis and/or modulating the immune system for optimization
of oncolytic viral therapy, with an emphasis on strategies that have
been employed specifically for treatment of HCC. These strategies
are summarized in Table 1.
COMBINATION THERAPIES
The rational design of combination therapies involving OVs and
existing clinical agents is a valuable strategy for improving thera-
peutic outcomes by employing synergistic mechanisms. Success
with several combination therapies for HCC has already been
reported. In an in vitro study, it was demonstrated that treat-
ment with parvovirus could sensitize p53-negative HCC cells to
the cytotoxic effects of cisplatin, and combination therapy resulted
in increased HCC cell death in comparison to either individual
therapy (70). Similarly, combination of adenovirus with the DNA-
intercalating drug, doxorubicin, resulted in synergistic cytotoxic
effects in vitro and significant inhibition of in vivo tumor growth
in preclinical HCC models (71). These results were confirmed by
an additional study in HCC, where it was shown that oncolytic
adenovirus sensitizes tumors to chemotherapy, and combinations
of adenovirus with 5-FU, doxorubicin, and paclitaxel all resulted
in enhanced efficacy in killing of HCC cells (72). A telomerase-
dependent replicating adenovirus (hTert-Ad) was also extremely
effective at sensitizing resistant HCC tumors to chemotherapy
via down-regulation of Mcl-1 expression, resulting in substan-
tial tumor responses in mice treated with virochemotherapy (87).
In another study using hTert-Ad, it was demonstrated that pro-
teasome inhibition with bortezomib led to endoplasmic reticu-
lum (ER) stress-induced apoptosis and improved anti-tumoral
immunity, leading to improved oncolysis of HCC (88). It was
further shown in this study that bortezomib inhibited anti-
viral immune responses in immunocompetent mice, allowing
enhanced viral kinetics of hTert-Ad, and indicating a dual benefit
of the combination therapy (88).
As an alternative to combination therapies involving
chemotherapy, we investigated the potential of applying a clin-
ical embolization agent together with oncolytic VSV to treat
HCC in an orthotopic rat model (89). In this study, we demon-
strated significantly enhanced tumor necrosis and prolongation
of survival in HCC-bearing rats treated by transarterial viroem-
bolization, as compared to monotherapy, and we attributed this
therapeutic effect to multiple mechanisms, including apoptosis,
anti-angiogenesis, and induction of anti-tumor immunity (89).
INHIBITION OR EVASION OF INFLAMMATORY RESPONSES
The direct cytopathic effect elicited by OVs is dependent on
their ability to evade immune surveillance long enough to allow
viral propagation to high titers and efficient spread of the vector
throughout the tumor mass. Because of the numerous physio-
logical and immunological barriers to oncolytic viral therapy in
the liver, several attempts were made to selectively block aspects
of the anti-viral response to improve and prolong viral repli-
cation prior to the launch of an adaptive immune response.
Although systemic suppression of immune responses has been
successful in promoting enhanced OV replication and intratu-
moral spread in various tumor models, there have been concerns
associated with the safety of such approaches (62). By incorporat-
ing genes encoding anti-inflammatory proteins directly into the
virus, we speculated that the suppression of immune responses
would be limited to the local area of virus replication within
the tumor, thereby dampening safety concerns. In nature, many
viruses have adapted themselves in various ways to counteract
or evade anti-viral immune responses to promote their own sur-
vival (68). One such mechanism involves the viral production of
chemokine-binding proteins (CKBPs), which are secreted pro-
teins that competitively bind to and/or inhibit the interactions
of immunomodulatory chemokines with their cognate receptors,
to block the chemotaxis of inflammatory cells (69). Based on
our observation that host inflammatory responses to VSV infec-
tion play a detrimental role in suppression of intratumoral viral
replication in HCC, we exploited several heterologously expressed
vCKBPs in order to enhance the oncolytic potency of VSV for the
treatment of HCC. Specifically, we engineered recombinant VSV
vectors encoding for the equine herpes virus-1 glycoprotein G and
the M3 gene from murine gammaherpesvirus-68, both of which
are broad range and high affinity vCKBPs (42, 90). Both recom-
binant vectors mediated the suppression of anti-viral NK cell and
neutrophil infiltration, which resulted in prolonged kinetics of
intratumoral VSV replication and significant survival prolonga-
tion in immune-competent, orthotopic liver tumor-bearing rats.
In order to specifically target the NK cell population, we incor-
porated the UL141 gene from human cytomegalovirus into VSV,
which specifically inhibits the NK cell-activating ligand CD155,
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resulting in enhanced virus propagation and tumor responses cor-
responding to inhibition of NK and NKT cell migration to infected
tumor sites (91). Importantly, none of these recombinant vectors
resulted in any observable signs of toxicity to the host, indicat-
ing that this strategy has potential for clinical translation in HCC
patients.
BOOSTING ANTI-TUMOR IMMUNITY
Due to the resistance of HCC to chemotherapy, and indica-
tions that immune responses have a direct effect on the clinical
course of the disease (92), HCC has become an attractive target
for immunotherapy. A variety of immunotherapeutics have been
tested in clinical trials for HCC patients, including cytokines,adop-
tive immune cells, and antibody-based therapies, and the resulting
data have indicated that these therapies are safe, even in the con-
text of underlying hepatic cirrhosis and HBV infection (93, 94).
Recent studies showing promising results involve adoptive DC
therapy, targeting of glypican-3, which is a tumor-associated anti-
gen (TAA) expressed by a high percentage of HCCs, or breaking
immune tolerance via antibody-mediated inhibition of cytotoxic
T-lymphocyte antigen 4 (CTLA4) (95, 96).
In addition to the direct cytopathic effect on tumor cells that
is induced by OVs, the stimulation of the host’s immune system
to launch an attack against cancer cells is a potent mechanism of
action that can be exploited by OV therapy. Particularly in tumors
where conditions are unfavorable to virus replication, due to fac-
tors such as IFN sensitivity, inflammation, or a high degree of
stroma and ECM, the effect of OV therapy can be rescued by uti-
lizing the vector as a cancer vaccine rather than as a direct oncolytic
agent. Although tumor cells express a variety of TAAs, a multitude
of mechanisms allow tumors to evade rejection from the host
immune system. The liver is a highly tolerogenic organ, due to fea-
tures of the microenvironment which induce immune tolerance
against foreign antigens (73), as evidenced by its susceptibility to
infection by hepatic viruses and to carcinogenesis and metastases.
OVs can serve to break the tolerance and enhance the immuno-
genicity of the tumor microenvironment as a potent therapeutic
mechanism. Viral oncolysis is associated with the local release of
TAAs, which can then be taken up by DCs. In addition, the release
of intrinsic cell factors, such as uric acid, can be recognized as a
danger signal to activate DCs (97). DCs are important compo-
nents of the innate immune response, and are key players in the
generation of adaptive immune responses via antigen presentation
and priming of T-cells. Virus-infected cells are highly effective in
delivering antigens for cross-presentation and cross-priming of
adaptive immune responses (98). Therefore, harnessing the inher-
ent ability of OVs to stimulate anti-tumoral immune responses is
a logical approach, and several such strategies have been employed
for HCC therapy.
Granulocyte–macrophage colony-stimulating factor (GM-
CSF) is a cytokine with strong immunostimulatory properties
that is secreted by macrophages, T-cells, fibroblasts, mast cells,
and endothelial cells. GM-CSF promotes progenitor cell differ-
entiation into DCs and can generate tumor-reactive CTL (74).
Gene transfer of GM-CSF to tumor cells augments tumor anti-
gen presentation by recruited DCs and macrophages to mediate
protective immunity against tumors (74, 75). To date, reports
of recombinant vaccinia virus, adenovirus, HSV, measles virus,
and NDV engineered to express GM-CSF have demonstrated
improved therapeutic outcomes due to enhanced anti-tumor
immune responses (76–80). In the context of HCC therapy, JX-
594, a thymidine kinase-deleted oncolytic vaccinia virus armed
with GM-CSF, resulted in partial responses with evidence of
efficacy in non-injected tumors, indicating that viral-mediated
immune stimulation played a role, in a phase I trial for therapy of
primary and secondary liver tumors (81). JX-594 was then applied
to a phase II clinical trial in patients with advanced HCC, where a
median survival of 14.1 months with high dose therapy compared
to 6.7 months for the low dose, was reported, implicating JX-594
as a highly promising vector for HCC therapy (82).
Along the same lines, other cytokines, such as IL-12, IL-24,
IL-2, and IFN-β (83–85, 99, 100) have been incorporated into
OVs. It has been hypothesized that virus-mediated expression of
IFN-β would improve tumor specificity by inhibiting viral repli-
cation in normal tissues while permitting propagation in tumors,
which possess various defects in type I IFN signaling. In addi-
tion, IFN-β can provide antiangiogenic effects (86) and thera-
peutic immune modulation via the induction of tumor-specific
cytotoxic T-lymphocyte responses (101). A recombinant VSV
expressing IFN-β was shown to enhance inflammatory cytokine
production and NK cell activation, leading to enhanced bystander
killing of tumor cells (100). Based on these results, rVSV-IFN-
β entered a phase I clinical trial for sorafenib-refractory HCC
in 2012 (NCT01628640). In a preclinical study, a conditionally
replicative adenovirus (CRAd) was engineered to express IFN-γ,
resulting in significant regression of HCC in mice through the
combined effects of viral-mediated oncolysis, anti-angiogenesis,
and anti-tumor immune responses (102).
Combination strategies involving the adoptive transfer of
immune cells together with OVs are an exciting new approach
which has shown striking efficacy in several models (103–105).
Although this strategy has not been extensively explored for HCC,
one study showed that a specific and strong immune response
against HCC cells could be elicited in vitro via patient-derived
DCs that were transduced with an adenoviral vector encoding
α-fetoprotein, a TAA often expressed in HCC, and co-cultured
with autologous cytokine-induced killer (CIK) cells (106). Strate-
gies involving engineering OVs to express a TAA to prime T-cell
responses have shown promise in other tumor models, such as
an engineered VSV vector expressing a TAA that resulted in an
antigen-specific CD8+ T-cell response in a murine melanoma
model (107), and will likely be explored further for HCC therapy
in the future.
OUTLOOK
Because of the rapid clearance of viruses in immune-competent
hosts, the therapeutic window during which OVs have the oppor-
tunity to replicate and cause their cytopathic effect in tumor cells
is relatively short. In the context of the liver microenvironment,
where myriad other barriers to OV propagation exist, we believe
that the immune system represents an essential tool, which must be
harnessed in order to destroy the remaining tumor cells that have
escaped viral infection. The combination of viral-mediated cytol-
ysis with tumor-directed immune stimulation creates a potent
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arsenal against hepatic tumors. Although two immunotherapeutic
OVs are already in clinical trials for HCC, there are many other
strategies for utilizing OVs to break immune tolerance and/or
stimulate anti-tumor immune responses, which have shown effi-
cacy in other tumor models but have not yet been tested in the
context of HCC.
One such strategy involves the exciting new concept of incor-
porating new molecules called “T-cell engagers” into oncolytic
viral vectors (108). In this approach, a secretory bispecific T-
cell engager, consisting of antibodies directed against CD3 and a
tumor cell-specific antigen, EphA2, was expressed by an oncolytic
vaccinia virus, and resulted in improved anti-tumor efficacy via
activation of T-cells within tumors and bystander cell killing
(109). Another innovative approach involves the systemic applica-
tion of oncolytic NDV, followed by intradermal vaccinations with
DCs pulsed with viral oncolysate, to prime naïve T-cells against
the patient’s TAAs and establish a long-lasting memory T-cell
repertoire (110). These novel strategies, which combine oncolytic
virotherapy with immunotherapy have the potential to produce
potent anti-tumor responses.
Alternatively, a prime-boost approach has been investigated, in
which two different recombinant OVs are sequentially adminis-
tered, the first one priming the immune response through expres-
sion of a TAA, followed by a boosted secondary response produced
by a subsequent TAA-encoding virus, leading to a robust tumor-
specific immunity (64, 111). A cDNA library has also been utilized
to present a broad range of TAAs by a recombinant VSV vector,
resulting in dramatic tumor regressions (112). These TAA-based
approaches lead to significant tumor responses via complementary
cell death mechanisms induced by the direct viral-mediated oncol-
ysis in combination with TAA-specific CD8+ T-cell-mediated
killing, causing additional TAAs to be released and presented by
DCs to T-cells and resulting in further activation of tumor-specific
immune responses, thereby conferring a potent arsenal against
systemic metastases.
A ubiquitous problem in the field of OV therapy is the rela-
tive inefficiency of systemic application, due to virus inactivation
by blood components, non-specific uptake by off-target cells, and
sequestration by the liver and spleen. To address this issue, var-
ious approaches using synthetic polymers or cell carrier systems
for viral shielding have been investigated (113). The innate abil-
ity of immune cells to home to tumors is a convenient feature,
which affords them the opportunity to serve as OV cell carriers
for the dual benefit of virus delivery and stimulation of anti-
tumor immune responses. To this end, VSV has been loaded
onto antigen-specific T-cells to simultaneously enhance adoptive
T-cell therapy, while providing a vehicle for OV delivery to the
tumor site (114). In similar studies, it was demonstrated that T-
cells, mature DCs, and CIK cells could efficiently deliver OVs to
their tumor targets to improve viral-mediated tumor oncolysis and
prime anti-tumor immune responses (65, 66). The application of
these approaches to HCC therapy will likely produce similar ben-
efits, and are undoubtedly already under investigation by several
groups.
As an alternative to the cell carrier approach for virus deliv-
ery, strategies involving the surface modification of OVs using
synthetic polymers have been developed to shield oncolytic vec-
tors from inactivation and non-specific uptake. VSV shielding via
covalent modification with polyethylene glycol (PEG) has resulted
in increased circulation times and a reduction of neutralizing
antibody responses (115). Polymer shielding of adenovirus has
been demonstrated to allow immune escape and a reduction of
liver sequestration by increasing the diameter above the size of
the hepatic sinusoidal fenestrae and by lowering KC uptake (67,
116). PEGylation of Ad5 with high molecular weight PEG (20 kD)
resulted in improved efficacy of intravenously applied therapy for
HCC, with reduced transduction of hepatocytes and KCs and
a reduction of hepatotoxicity (117), making this an attractive
approach for improving the specificity of OV therapies targeted to
liver tumors.
CONCLUDING REMARKS
The complex liver milieu underlying HCC presents innumerable
challenges to the development of effective therapeutic agents to
produce significant tumor responses and prolongation of patient
survival. However, by gaining a greater understanding of the
dynamic roles of the hepatic microenvironment and the patho-
genesis of liver disease and carcinogenesis, we can actually exploit
the properties of the local liver setting to synergize with ther-
apeutic agents. Because OVs exert their therapeutic effects via
multiple mechanisms, including direct cytopathic effects, anti-
angiogenesis, and anti-tumor immune stimulation, they represent
ideal agents for contending with the liver microenvironment.
This is evidenced by recent reports, which demonstrate that OVs
not only provide potent anti-tumor effects, but they also possess
antifibrotic and anti-viral properties, allowing them to provide
therapeutic benefits against the underlying liver injury. Therefore,
by discerning the complexities of the liver microenvironment and
their roles in the pathogenesis of HCC, Pandora’s box of evil is
converted to a vessel of hope, for which OVs will surely play an
important role in providing synergistic therapeutic outcomes.
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